Between March 2017 and January 2018 Dupilumab was approved in four major global regions: the US[1], the EU[2], Canada[3], and Japan.[4]

Following this success, in June 2018, the National Institute for Health and Care Excellence (NICE) has published a positive Final Appraisal Determination (FAD) that recommends the use of dupilumab in combination with topical corticosteroids as routine practise in the National Health Service (NHS) in England for adult patients with moderate to severe atopic dermatitis who  have not responded to at least one systemic therapy.[5]

For further information related to the first approval of dupilumab please visit Drugs[6], or to learn more about the overall development of dupilumab across all indications visit AdisInsight.[7]

Image credit: Katya Austin – Unsplash

Leave a Reply

This site uses Akismet to reduce spam. Learn how your comment data is processed.